APP and Alzheimer disease: Treatment with α-MSH preserved the expression of the GABAergic marker GAD67 (glutamic acid decarboxylase 67) promoted the survival of GABAergic GAD67+ inhibitory interneurons in the hippocampus and improved spatial memory in the TgCRND8 mouse model of AD with Swedish and Indiana mutations in APP [100].